Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, post-traumatic stress disorder (PTSD), and associated disorders.
This initiative targets underserved conditions in the central nervous system (CNS) space, where treatment options are limited. TBI affects millions worldwide, often leading to long-term cognitive and psychological impairments. Current therapies primarily manage symptoms rather than address underlying pathology. By leveraging ibogaine, a compound traditionally used in addiction treatment, Silo aims to develop novel interventions that could potentially modify disease progression.
The patent application represents an early step in securing intellectual property for this approach. Details on the specific compositions and methods are not disclosed, but the filing indicates the company's commitment to advancing ibogaine-based treatments. Silo's therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and CNS diseases. Its pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis, all conducted in collaboration with leading universities and laboratories.
This move positions Silo at the intersection of psychedelic research and neurology. Ibogaine has shown promise in treating substance use disorders, but its application for TBI is relatively unexplored. The announcement could stimulate further research into ibogaine's neuroprotective and neuroregenerative properties. For patients and healthcare providers, this represents a potential new avenue for addressing the complex sequelae of TBI, which currently lacks effective pharmacological treatments.
The company's decision to pursue this initiative underscores a broader industry trend toward repurposing psychedelic compounds for neurological conditions. With regulatory frameworks evolving, Silo's early patent filing may provide a competitive advantage. However, development timelines remain uncertain, as preclinical and clinical trials are necessary to validate safety and efficacy.
Investors and stakeholders should monitor updates from Silo Pharma regarding this initiative. Further details about the patent and development plans are expected in future announcements. The company's newsroom at https://ibn.fm/SILO provides ongoing updates.
